NCT05636111 2026-01-22Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian CancerM.D. Anderson Cancer CenterPhase 1 Recruiting34 enrolled
NCT04607954 2026-01-06Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung CancerMayo ClinicPhase 2 Active not recruiting29 enrolled